Athenea Biomédica

9. Bankir L. Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects. Cardiovasc Res. 2001 Aug 15;51(3):372-90.

10. Riddell DC, Mallonee R, Phillips JA, Parks JS, Sexton LA, Hamerton JL. Chromosomal assignment of human sequences encoding arginine vasopressin-neurophysin II and growth hormone releasing factor. Somat Cell Mol Genet.

1985;11(2):189-95.

11. Robertson GL. The regulation of vasopressin function in health and disease. Recent Prog Horm Res. 1976;33:333-85.

12. Leng G, Brown CH, Russell JA. Physiological pathways regulating the activity of magnocellular neurosecretory cells. Prog Neurobiol. 1999;57(6):625-55.

13. Chauvet MT, Chauvet J, Acher R. Guinea pig copeptin. The glycopeptide domain of the vasopressin precursor. FEBS Lett.

1986;197(1-2):169-72.

14. Robertson GL. Antidiuretic hormone. Normal and disordered function. Endocrinol Metab Clin North Am. 2001;30(3):671-94.

15. Baumann G, Dingman JF. Distribution, blood transport, and degradation of antidiuretic hormone in man. J Clin Invest.

1976;57(5):1109-16.

16. Morgenthaler NG, Struck J, Jochberger S, Dünser MW. Copeptin: clinical use of a new biomarker. Trends Endocrinol Metab. 2008 Mar;19(2):43-9.

17. Kwon TH, Hager H, Nejsum LN, Andersen ML, Frøkiaer J, Nielsen S. Physiology and pathophysiology of renal aquaporins. Semin Nephrol. 2001;21(3):231-8.

18. Birnbaumer M. Vasopressin receptors. Trends Endocrinol Metab. 2000;11(10):406-10.

19. Morel A, O’Carroll AM, Brownstein MJ, Lolait SJ. Molecular cloning and expression of a rat V1a arginine vasopressin receptor. Nature. 1992 Apr 9;356(6369):523-6.

20. Folny V, Raufaste D, Lukovic L, Pouzet B, Rochard P, Pascal M, Serradeil-Le Gal C. Pancreatic vasopressin V1b receptors: characterization in In-R1-G9 cells and localization in human pancreas. Am J Physiol Endocrinol Metab.

2003;285(3):E566-76.

21. Holmes CL, Landry DW, Granton JT. Science review: Vasopressin and the cardiovascular system part 1--receptor physiology. Crit Care. 2003;7(6):427-34.

22. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin Clin Chem. 2006;52(1):112-9.

23. Holwerda DA. A glycopeptide from the posterior lobe of pig pituitaries. I. Isolation and characterization. Eur J Biochem.

1972;28(3):334-9.

24. Bhandari SS, Loke I, Davies JE, Squire IB, Struck J, Ng LL. Gender and renal function influence plasma levels of copeptin in healthy individuals. Clin Sci (Lond). 2009;116(3):257-63.

25. Arnlöv J, Evans JC, Meigs JB, Wang TJ, Fox CS, Levy D, Benjamin EJ, D’Agostino RB, Vasan RS. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation. 2005;112(7):969-75.

26. Bouby N, Ahloulay M, Nsegbe E, Déchaux M, Schmitt F, Bankir L. Vasopressin increases glomerular filtration rate in conscious rats through its antidiuretic action. J Am Soc Nephrol. 1996 Jun;7(6):842-51.

27. Bardoux P, Bichet DG, Martin H, Gallois Y, Marre M, Arthus MF, Lonergan M, Ruel N, Bouby N, Bankir L. Vasopressin increases urinary albumin excretion in rats and humans: involvement of V2 receptors and the renin-angiotensin system.

Nephrol Dial Transplant. 2003;18(3):497-506.

28. Bankir L, Trinh-Trang-Tan MM. Urea and the kidney. In: Brenner BM, editor. The Kidney. Sixth edition. Philadelphia: WB Saunders Company; 2000. p 637.

29. Okada H, Suzuki H, Kanno Y, Yamamura Y, Saruta T. Effects of vasopressin V1 and V2 receptor antagonists on progressive renal failure in rats. Clin Sci (Lond). 1994;86(4):399-404.

30. Bardoux P, Bruneval P, Heudes D, Bouby N, Bankir L. Diabetes-induced albuminuria: role of antidiuretic hormone as revealed by chronic V2 receptor antagonism in rats. Nephrol Dial Transplant. 2003;18(9):1755-63.

31. Fernandes S, Bruneval P, Hagege A, Heudes D, Ghostine S, Bouby N. Chronic V2 vasopressin receptor stimulation increases basal blood pressure and exacerbates deoxycorticosterone acetate-salt hypertension. Endocrinology. 2002;143(7):2759-66.

32. Meijer E, Bakker SJ, Halbesma N, de Jong PE, Struck J, Gansevoort RT. Copeptin, a surrogate marker of vasopressin, is associated with microalbuminuria in a large population cohort. Kidney Int. 2010;77(1):29-36.

33. Meijer E, Bakker SJ, de Jong PE, Homan van der Heide JJ, van Son WJ, Struck J, Lems SP, Gansevoort RT. Copeptin, a surrogate marker of vasopressin, is associated with accelerated renal function decline in renal transplant recipients.

Transplantation. 2009;88(4):561-7.

34. Dünser MW, Schmittinger CA, Torgersen C. Copeptin and the transplanted kidney: friends or foes? Transplantation.

2009;88(4):455-6.